FLAGSHIP PIONEERING INC
Q2 2022 Form 13-F

CAMBRIDGE, MASSACHUSETTS
CIK 0001400240 · Institutional investment manager
Consolidated report · includes 1 manager since Q3 2016
$2.7B Reported Value Total
Reported value
$2.7B
Quarter over quarter
-22.7%
Holdings
12
Top-10 concentration
99.6%

Filing Structure

Reports holdings for

  • Flagship Ventures Fund V General Partner LLC · File #028-18466 · Q4 2017 – Q3 2025
  • Afeyan Noubar · File #028-19988 · Q1 2024 – Q1 2025 · declared by one filing
  • Flagship Pioneering Fund VI General Partner LLC (not a 13F filer in our records) · File #028-20998 · Q4 2020 – Q3 2022
  • Flagship Ventures Opportunities Fund I General Partner LLC (not a 13F filer in our records) · File #028-20999 · Q4 2020 – Q3 2022 · declared by one filing
  • Nutritional Health LTP Fund General Partner LLC (not a 13F filer in our records) · File #028-21001 · Q4 2020 – Q3 2022 · declared by one filing
  • Flagship Pioneering Special Opportunities Fund II General Partner LLC (not a 13F filer in our records) · File #028-20997 · Q4 2020 – Q3 2022 · declared by one filing
  • Flagship Opportunities Fund I General Partner LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Flagship Pioneering Fund VI General Partner LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Flagship Pioneering Special Opportunities Fund II General Partner LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Nutritional Health Fund LTP General Partner LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Noubar Afeyan (not a 13F filer in our records) · Q4 2019 – Q4 2019 · declared by one filing
  • Flagship Ventures 2007 General Partner LLC (not a 13F filer in our records) · File #028-15778 · Q3 2016 – Q3 2017

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Ph.d. Noubar B. Afeyan
Sole Member and Manager of Manager
Q1 2022
Q3 2022
Go to latest
Loading 13F Metrics

Q2 2022 13F filing summary

Period of report June 30, 2022
Filed August 15, 2022
Form 13F-HR
Reported value $2.7B
Positions 12
Change in reported value -37.7%
New positions 0
Exited positions 1
Position turnover 7.7%
Top-10 concentration 99.6%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
 5 $1.5B
Q1 2026 13F
Filed May 15, 2026
 5 $1.2B
Q4 2025 13F
Filed Feb 17, 2026
 4 $324.0M
Q3 2025 13F
Filed Nov 14, 2025
 4 $292.6M
Q2 2025 13F
Filed Aug 14, 2025
 4 $268.5M
Q1 2025 13F
Filed May 15, 2025
 4 $235.8M
Q4 2024 13F
Filed Feb 14, 2025
 5 $334.2M
Q3 2024 13F
Filed Nov 14, 2024
 6 $591.9M
Q2 2024 13F
Filed Aug 14, 2024
 6 $843.4M
Q1 2024 13F
Filed May 15, 2024
 7 $1.5B
Q4 2023 13F
Filed Feb 14, 2024
 7 $1.3B
Q3 2023 13F
Filed Nov 14, 2023
 9 $1.4B
Q2 2023 13F
Filed Aug 14, 2023
 10 $2.2B
Q1 2023 13F
Filed May 15, 2023
 11 $2.6B
Q4 2022 13F
Filed Feb 14, 2023
 12 $3.1B
Q3 2022 13F
Filed Nov 14, 2022
 12 $2.4B
Q2 2022 13F
Filed Aug 15, 2022
 12 $2.7B
Q1 2022 13F
Filed May 16, 2022
 13 $4.3B
Q4 2021 13F
Filed Feb 14, 2022
 13 $6.5B
Q3 2021 13F
Filed Nov 15, 2021
 13 $9.5B

20 earlier quarters on file — choose one from the quarter menu above.

Top 12 holdings · Q2 2022

# Holding Reported value % of portfolio
1 MRNA Moderna Inc $1.8B 69.35%
2 SANA Sana Biotechnology Inc $220.2M 8.29%
3 FHTX Foghorn Therapeutics Inc $172.4M 6.49%
4 EVLO Evelo Biosciences Inc $106.4M 4.01%
5 OMGA Omega Therapeutics Inc $98.4M 3.71%
6 DNLI Denali Therapeutics Inc $77.1M 2.9%
7 MCRB Seres Therapeutics Inc $49.3M 1.86%
8 AXLA Axcella Health Inc $38.3M 1.44%
9 RUBY Rubius Therapeutics Inc $32.7M 1.23%
10 SGTX Sigilon Therapeutics Inc $8.6M 0.32%
11 CDAKQ Codiak Biosciences Inc $7.5M 0.28%
12 SYRS Syros Pharmaceuticals Inc $2.8M 0.11%

Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings